Bladder cancer research: Impact of FGFR2/3 activating genomic alterations on response to enfortumab vedotin in metastatic urothelial carcinoma (mUC) Senior author: Guru Sonpavde, MD ASCO #GU21 Abstract 472
when patients who have an f g f r three or F g f R two activating genomic alteration as we know era freedom, it is approved. This is an oral FGF are targeting terrorism, kindness a nebula. So the question has been in patients with this alteration. Do we use and photograph first or LDA Brittany first? That's one question. The second question is how active is an photo map valid in in patients with F G far three, or or to activating genomic alterations. So what we did was we corrected patients with metastatic carcinoma who had received in Fort Mac peloton, uh, in the post Platinum and Period one l one in a bit of setting. And we also selected only those patients where we had the somatic genomic profiling done. So we had the chief are three or two status? No. The bottom line is, it seemed like having the f t f R three or two activating genomic alteration did not appear to compromise responses to inform the map meditation. So it seems like, and Fordham at Balaton is indeed active. Uh, to a similar extent in patients with the FGF are clear to activating genomic alteration compared to patients who did not have it. So I think that is reassuring and suggest that in patients with the alteration, um, either a referendum that first or in front of my ballot and 1st may not matter again. This is retrospective too early. I think it needs for the validation. Uh, and this is by no means a definitive study. And we I think we need a larger data set, but I think this is reassuring to, um to know that in front of my belly button has, uh, similar activity in f g f R three activating mutations as opposed to those who do not.
Related Presenters
